Eduardo Gonzalez-Toledo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eduardo Gonzalez-Toledo has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Gaudet
LSU Health Shreveport School of Medicine, Louisiana State University Shreveport, Shreveport, LA 71103, USA
1 shared publication - Alexas Gaudet
LSU Health Shreveport School of Medicine, Louisiana State University Shreveport, Shreveport, LA 71103, USA
1 shared publication - Felicity N. E. Gavins
Department of Life Sciences Centre for Inflammation Research and Translational Medicine (CIRTM) Brunel University London London UB8 3PH UK
1 shared publication - Harish Siddaiah
Department of Anesthesiology, Louisiana State University Health Sciences Center Shreveport, Shreveport, USA
1 shared publication - Hugo H. Cuellar-Saenz
Department of Neurosurgery and Interventional Neuroradiology, Louisiana State University, Shreveport, Louisiana, USA
1 shared publication - Junaid Ansari
Department of Neurology, Louisiana State University Health Shreveport, Shreveport, LA
1 shared publication
Latest Publications
- Open Access
- 13 February 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (2) , 435
The Spectrum of Acute Cerebrovascular Disease in Patients with COVID-19
(1) Background: COVID-19 infection is responsible for the ongoing pandemic and acute cerebrovascular disease (CVD) has been observed in COVID-19 patients. (2) Methods: We conducted a retrospective, observational study of hospitalized adult patients admitted to our hospital with SARS-CoV-2 and acute cerebrovascular disease. All clinical data were reviewed including epidemiology, clinical features, laboratory data, neuroradiological findings, hospital management and course from 32 patients hospitalized for COVID-19 management with acute cerebrovascular disease. (3) Results: Acute CVD with COVID-19 was associated with higher NIH stroke scale on discharge compared to non-COVID-19 CVDs. Seizures complicated the hospital course in 16% of COVID-19 patients with CVD. The majority of the acute CVDs were ischemic (81%) in nature followed by hemorrhagic (22%). Acute CVD with COVID-19 resulted in average hospital stays greater than twice that of the control group (13 days in COVID-19, 5 days in control). Acute CVD with COVID-19 patients had worse clinical outcomes with 31% patient deaths and 6% discharged to hospice. In the control group, 6% of patients died. (4) Conclusions: Acute CVD associated with COVID-19 tends to be more complicated with unique and adverse clinical phenotype, longer hospital admissions, and worse clinical outcomes.
- 13 February 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (2) , 435
Open AccessThe Spectrum of Acute Cerebrovascular Disease in Patients with COVID-19
(1) Background: COVID-19 infection is responsible for the ongoing pandemic and acute cerebrovascular disease (CVD) has been observed in COVID-19 patients. (2) Methods: We conducted a retrospective, observational study of hospitalized adult patients admitted to our hospital with SARS-CoV-2 and acute cerebrovascular disease. All clinical data were reviewed including epidemiology, clinical features, laboratory data, neuroradiological findings, hospital management and course from 32 patients hospitalized for COVID-19 management with acute cerebrovascular disease. (3) Results: Acute CVD with COVID-19 was associated with higher NIH stroke scale on discharge compared to non-COVID-19 CVDs. Seizures complicated the hospital course in 16% of COVID-19 patients with CVD. The majority of the acute CVDs were ischemic (81%) in nature followed by hemorrhagic (22%). Acute CVD with COVID-19 resulted in average hospital stays greater than twice that of the control group (13 days in COVID-19, 5 days in control). Acute CVD with COVID-19 patients had worse clinical outcomes with 31% patient deaths and 6% discharged to hospice. In the control group, 6% of patients died. (4) Conclusions: Acute CVD associated with COVID-19 tends to be more complicated with unique and adverse clinical phenotype, longer hospital admissions, and worse clinical outcomes.